Your session is about to expire
← Back to Search
Topical Roflumilast for Plaque Psoriasis (DERMIS-OLE Trial)
DERMIS-OLE Trial Summary
This trial will study a new cream to treat plaque psoriasis. The cream will be applied once a day for 24 weeks.
DERMIS-OLE Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.DERMIS-OLE Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Group 1: ARQ-151 Cream 0.3%
Frequently Asked Questions
Are patients being actively sought for this experiment?
"This particular clinical trial, as recorded on the website clinicaltrials.gov, is not currently looking for patients to participate. This study was originally posted on February 12th 2020 and updated November 9th of 2022. There are, however, 189 other trials that are recruiting patients."
Does the age limit for this test extend past 25 years old?
"According to the eligibility requirements listed on this clinical trial, patients must be aged 2-11. There are a total of 33 clinical trials for children under 18 and 160 for adults over 65 years old."
What are the possible side effects of using Topical roflumilast?
"Topical roflumilast has undergone multiple rounds of testing and has been proven effective, making it a safe choice with a score of 3."
How many people are being allowed to participate in this trial?
"Unfortunately, this trial is not looking for new patients at the moment. The listing was first created on February 12th 2020 and edited most recently on November 9th 2022. However, there are presently 179 other trials actively recruiting psoriasis patients and 10 topical roflumilast studies also admitting participants."
How can I sign up for this opportunity to participate in this research?
"Eligibility for this psoriasis study requires that patients be aged 2-11. Up to 285 individuals will be enrolled in the clinical trial."
How many different medical centers are conducting this experiment?
"83 clinical sites are running this study, including Arcutis Biotherapeutics Clinical Site 509 in Fountain Valley, Pennsylvania, Arcutis Biotherapeutics Clinical Site 511 in Rancho Santa Margarita, Texas, and Arcutis Biotherapeutics Clinical Site 113 in Exton, North carolina."
Is roflumilast the first medication of its kind?
"Roflumilast was first trialed in 2018 at Mays Cancer Center, UT Health San Antonio. Since then, there have been 47 completed studies with roflumilast. Presently, 10 clinical trials are recruiting patients with several of these based in Fountain Valley, Pennsylvania."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger